Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Study of Marstacimab Prophylaxis vs Standard Treatment in Severe Hemophilia A and Moderately Severe to Severe Hemophilia B
jRCT2080225164Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label trial of marstacimab in hemophilia A and hemophilia B (HB) (4 cohorts), sponsored by Pfizer. Primary endpoint: Primary efficacy and safety endpoints. Started Apr 2020; status: completed.
02
Drugs
marstacimab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on jRCT2080225164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225164.